Lumexa Imaging hauled in $462.5 million during its initial public offering, far exceeding the $200 million the outpatient ...

Invea Therapeutics, a biotech company developing drugs for conditions such as psoriasis, has filed for an IPO on the Nasdaq ...

The U.S. IPO activity looks sluggish amid the holiday-shortened week. Nevertheless, the week prior saw Texas-based cybersecurity firm SailPoint price its upsized IPO of 60M shares at a public offering ...

MapLight Therapeutics is hoping to raise up to $262 million from its IPO, with the proceeds earmarked for its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy. The California-based ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

Akston Biosciences Corp., pet medicines company, has filed paperwork with the U.S. Securities and Exchange Commission to begin the initial public offering process.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Good morning, Boston, and happy Friday. Here are the five ...

Jyong Biotech aims to raise $18.8 million in a US IPO. The company develops plant-based treatments for urinary diseases but faces FDA efficacy doubts and high legal cost exposure. Financially, Jyong ...

Seventy-three pharmaceutical, biotechnology and medical device companies from mainland China filed for IPOs in Hong Kong this year, a review by BioWorld found. In the second half of 2025, 43 new ...

From biotech to AI, December's listings - including at least 15 down the stretch - crown the city's revival in equity fundraising Hong Kong's initial public offering (IPO) market is heading for its ...